3-hydroxybutyric acid has been researched along with Diabetic Angiopathies in 2 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arildsen, L | 1 |
Andersen, JV | 1 |
Waagepetersen, HS | 1 |
Nissen, JBD | 1 |
Sheykhzade, M | 1 |
Ferrannini, E | 1 |
Mark, M | 1 |
Mayoux, E | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus[NCT05164263] | Phase 4 | 156 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | ||
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes[NCT02964715] | Phase 4 | 25 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at High Cardiovascular Risk: The SIMPle Randomized Clinical Trial[NCT03151343] | Phase 3 | 92 participants (Actual) | Interventional | 2017-03-29 | Completed | ||
Effect of a Quadruple Therapy on Pancreatic Islet Function, Insulin Resistance and Cardiovascular Function in Patients With Mixed Prediabetes and Obesity: Randomized Clinical Trial[NCT04131582] | Phase 3 | 34 participants (Anticipated) | Interventional | 2019-09-01 | Recruiting | ||
Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes[NCT03887416] | Phase 4 | 225 participants (Anticipated) | Interventional | 2019-04-12 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 other studies available for 3-hydroxybutyric acid and Diabetic Angiopathies
Article | Year |
---|---|
Hypermetabolism and impaired endothelium-dependent vasodilation in mesenteric arteries of type 2 diabetes mellitus db/db mice.
Topics: 3-Hydroxybutyric Acid; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, An | 2019 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |